Sharing is caring!


Merck & Co. partners with Volansi to test deliver cold chain products straight from manufacturing facility to a health clinic.

Merck is testing using Volansi’s VOLY C10 drone to deliver vaccines and medicinal products from its facility to a nearby health clinic.

This project was initiated in hopes of meeting the critical and urgent needs of vaccines or medicinal products.

The use of drones is the latest innovation in the cold-chain logistics industry and according to Volansi, it is a safer way of delivering cold chain products as the delivery is made immediately upon receiving the shipment and taken directly to the delivery point.

However, more testing and research remain before officially using it in a logistic process.

(Source: BioProcess International, 2020)


Brazil’s health regulator allows the resumption of Sinovac’s COVID-19 vaccine trials.

Brazil’s health regulator recently allowed the resumption of the late-stage clinical trials for China’s Sinovac COVID-19 vaccine after it has been suspended because of the death of a study participant, which was eventually ruled as suicide.

After the health regulator in Brazil evaluated the new data presented by Sinovac, they permitted them to resume its clinical trials in Brazil.

Brazil currently has one of the world’s worst COVID-19 outbreaks, with over 5.7 million confirmed cases and 163,000 deaths related to the virus as to date.

(Source: Channel News Asia, 2020)


Pfizer says COVID-19 vaccine is 90% effective

Pfizer recently announced that its COVID-19 vaccine candidate which was jointly developed with BioNTech was shown 90 percent effective in preventing COVID-19 infections in its ongoing phase 3 trials.

According to their preliminary findings, protection against COVID-19 in patients was achieved seven days after the second of two doses, and 28 days after the first dose. The findings are based on an interim analysis conducted after 94 participants contracted the novel COVID-19 virus.

The trial will continue until 164 cases have occurred and expect two months of safety follow-up data, a key metric required by US regulators before they sought an emergency authorization for use.

Pfizer expects to supply up to 50 million vaccine doses around the world in 2020 and 1.3 billion in 2021.

(Source: The Straits Times, 2020)